New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Pr
30 Maio 2007 - 9:05AM
Business Wire
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global
biopharmaceutical company, today announced that multiple studies of
ABRAXANE� for Injectable Suspension (paclitaxel protein-bound
particles for injectable suspension) (albumin bound) will be
presented at the 43rd Annual Meeting of the American Society of
Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be
presented from studies which highlight the potential utility of
ABRAXANE (ABI-007) as a single-agent and in combination for the
treatment of breast, lung and ovarian cancers. An updated analysis
of the study titled �A Randomized Phase II Study of Weekly or Every
3 Weeks ABI-007 vs. Every 3 Weeks Taxotere� as First Line Therapy
of Stage IV Metastatic Breast Cancer� (Abstract 1032) will be
presented as a poster on Saturday, June 2, 2007 from 8 a.m. to 12
p.m. (Room S403), with a poster discussion following from 12 p.m.
to 1 p.m., S406 (Vista Room). The updated analysis of the Phase II
study evaluates first-line treatment ABRAXANE given weekly and
every three weeks compared to Taxotere� (docetaxel) dosed every
three weeks in patients with metastatic breast cancer. Interim
results of this study were presented at the San Antonio Breast
Cancer Symposium in December 2006. Abraxis is continuing to expand
its clinical experience with ABRAXANE and its potential in treating
multiple tumor types as a single agent and in combination. Data
from company and investigator-sponsored studies in breast, lung and
ovarian cancer will be presented during the poster presentations
including: BREAST CANCER Randomized study comparing nab-paclitaxel
with solvent-based paclitaxel in Chinese patients (pts) with
metastatic breast cancer (MBC) (Abstract 1038) Poster Presentation:
Saturday, June 2, 8:00 a.m. to 12:00 p.m., Room S403 Poster
Discussion: Saturday, June 2, 12 p.m. to 1 p.m., Room S406 (Vista
Room) NCCTG Phase II trial N0531 of weekly nab-paclitaxel (nab-p)
in combination with gemcitabine (gem) in patients with metastatic
breast cancer (MBC) (Abstract 1048) Poster Presentation: Saturday,
June 2, 2 p.m. to 6 p.m., S Hall A2 Phase II trial of
nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) +
capecitabine (XEL) in first-line treatment of metastatic breast
cancer (MBC): Interim Results (Abstract 1053) Poster Presentation:
Saturday, June 2, 2 p.m. to 6 p.m., S Hall A2 Randomized phase II
trial of three dosing schedules of nanoparticle albumin-bound
paclitaxel with bevacizumab as 1st-line therapy for HER2 negative
metastatic breast cancer: An initial interim safety report
(Abstract 1104) Poster Presentation: Saturday, June 2, 2 p.m. to 6
p.m., S Hall A2 LUNG CANCER Study of three weekly nab-paclitaxel
regimens in combination with carboplatin as first line therapy in
advanced non-small cell lung cancer (NSCLC) (Abstract 7659) Poster
Presentation: Sunday, June 3, 8 a.m. to 12 p.m., S Hall A2 An
open-label, Phase II trial of nanoparticle albumin bound paclitaxel
(nab-paclitaxel), carboplatin, and bevacizumab in first-line
patients with advanced non-squamous non-small cell lung cancer
(NSCLC) (Abstract 7610) Poster Presentation: Sunday, June 3, 8 a.m.
to 12 p.m., S Hall A2 OVARIAN CANCER Results of a Phase II
evaluation of nanoparticle albumin bound paclitaxel
(nab-paclitaxel) in platinum-sensitive patients with recurrent
ovarian, peritoneal, or fallopian tube cancer (Abstract 5525)
Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., Room E451a
Poster Discussion: Sunday, June 3, 11 a.m. to 12 p.m., Room E354a
About ABRAXANE The U.S. Food and Drug Administration approved
ABRAXANE for Injectable Suspension (paclitaxel protein-bound
particles for injectable suspension) (albumin-bound) in January
2005 for the treatment of breast cancer after failure of
combination chemotherapy for metastatic disease or relapse within
six months of adjuvant chemotherapy. Prior therapy should have
included an anthracycline unless clinically contraindicated. For
the full prescribing information for ABRAXANE, please visit
www.abraxane.com. ABRAXANE was developed by Abraxis BioScience,
Inc. ABRAXANE is marketed in the United States under a co-promotion
agreement between Abraxis BioScience, Inc. and AstraZeneca
Pharmaceuticals LP. About Abraxis BioScience, Inc. Abraxis
BioScience, Inc. is an integrated global biopharmaceutical company
dedicated to meeting the needs of critically ill patients. The
company develops, manufactures and markets one of the broadest
portfolios of injectable products and leverages revolutionary
technology such as its nabTM platform to discover and deliver
breakthrough therapeutics that transform the treatment of cancer
and other life-threatening diseases. The first FDA approved product
to use this nab platform, ABRAXANE, was launched in 2005 for the
treatment of metastatic breast cancer. Abraxis trades on the Nasdaq
Global Market under the symbol ABBI. For more information about the
company and its products, please visit www.abraxisbio.com.
Taxotere� is a registered trademark of Sanofi-Aventis.
Abraxis Bioscience (MM) (NASDAQ:ABBI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Abraxis Bioscience (MM) (NASDAQ:ABBI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024